Tuberculosis treatment outcome in the European Union and European Economic Area: an analysis of surveillance data from 2002‒2011.

Tuberculosis treatment outcome in the European Union and European Economic Area: an analysis of surveillance data from 2002‒2011. Euro Surveill. 2015 Dec 10;20(48) Authors: Karo B, Hauer B, Hollo V, van der Werf MJ, Fiebig L, Haas W Abstract Monitoring the treatment outcome (TO) of tuberculosis (TB) is essential to evaluate the effectiveness of the intervention and to identify potential barriers for TB control. The global target is to reach a treatment success rate (TSR) of at least 85%. We aimed to assess the TB TO in the European Union and European Economic Area (EU/EEA) between 2002 and 2011, and to identify factors associated with unsuccessful treatment. Only 18 countries reported information on TO for the whole observation period accounting for 250,854 new culture-confirmed pulmonary TB cases. The 85% target of TSR was not reached in any year between 2002 and 2011 and was on average 78%. The TSR for multidrug-resistant (MDR)-TB cases at 24-month follow-up was 49%. In the multivariable regression model, unsuccessful treatment was significantly associated with increasing age (odds ratio (OR) = 1.02 per a one-year increase, 95% confidence interval (CI): 1.02-1.02), MDR-TB (OR = 8.7, 95% CI: 5.09-14.97), male sex (OR = 1.40, 95% CI: 1.28-1.52), and foreign origin (OR = 1.32, 95% CI: 1.03-1.70). The data highlight that special efforts are required for patients with MDR-TB and the elderly aged ≥...
Source: Euro Surveill - Category: Infectious Diseases Authors: Tags: Euro Surveill Source Type: research

Related Links:

Source: International Journal of Tuberculosis and Lung Disease - Category: Respiratory Medicine Authors: Tags: ORIGINAL ARTICLES Source Type: research
Source: International Journal of Tuberculosis and Lung Disease - Category: Respiratory Medicine Authors: Tags: ORIGINAL ARTICLES Source Type: research
ABSTRACT: Introduction: The mortality rate among tuberculosis patients (TB fatality) has been attributed to irregular chemotherapy, delay in diagnosis, multidrug resistance, and HIV coinfection. Objective: To analyze TB fatality rates by sex, clinical presentation and HIV coinfection in Campinas, S ão Paulo, Brazil. Methods: Cohorts of residents in the city of Campinas who either died during treatment for tuberculosis or had the disease confirmed after death were divided into three intervals: 2001-2003, 2004-2006, and 2007-2009. Data were obtained from the database of the Tuberculosis Surve illance System of the Uni...
Source: Revista Brasileira de Epidemiologia - Category: Epidemiology Source Type: research
Conclusions: MDR-TB can be cured successfully with modified DOTS-Plus strategy and requires much effort from both the patients and health-care workers. It can be an alternative model for treating MDR-TB patients in private sector.
Source: Lung India - Category: Respiratory Medicine Authors: Source Type: research
At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaquiline and delamanid was a critical deve...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Study protocol Source Type: research
Authors: Bozok T, Kayar B, Yakıcı G, Eker E, Marzi M, Karslı F, Köksal F Abstract Tuberculosis (TB) is a chronic, granulomatous and necrotizing disease caused by microorganisms belonging to the Mycobacterium tuberculosis complex group. In 2017, 6.4 million new TB cases have been reported according to the World Health Organization 2018 Global Tuberculosis Report. TB remains among the major health problems of our time due to the increasing drug resistance problem and the difficulties in definitive diagnosis in recent years. It is stated by clinicians that intensive use of quinolone group drugs with oral form ...
Source: Mikrobiyoloji Bulteni - Category: Microbiology Tags: Mikrobiyol Bul Source Type: research
Substantial efforts are currently focused on investigating and developing new multidrug-resistant tuberculosis (MDR-TB) drugs and diagnostic methods. In Yemen, however, the evaluation of health-related quality...
Source: Health and Quality of Life Outcomes - Category: International Medicine & Public Health Authors: Tags: Research Source Type: research
Multidrug-resistant tuberculosis (MDR-TB) in HIV endemic settings is a major threat to public health. MDR-TB is a substantial and underreported problem in Sub-Saharan Africa (SSA), with recognised cases projec...
Source: BMC Infectious Diseases - Category: Infectious Diseases Authors: Tags: Research article Source Type: research
ConclusionThe frequency of mutations in MTB in the coastal region of Andhra Pradesh, India, is similar to that in retreatment cases from most settings, with close to 80% in rpoB codon 516, 526, and 531, and over 80% in codons katG 315 and/or inhA promoter. The increase in INH monoresistance underlines the need for greater enforcement of national TB control programs.
Source: The Brazilian Journal of Infectious Diseases - Category: Infectious Diseases Source Type: research
The US Food and Drug Administration green lights a therapy for an extreme form of multidrug resistant TB.
Source: The Scientist - Category: Science Tags: News & Opinion Source Type: news
More News: Infectious Diseases | Multidrug Resistance | Tuberculosis